Eli Lilly and Company
LLY · NYSE
LLY · NYSE
Eli Lilly is a large-cap pharmaceutical company that earns revenue by discovering, developing, manufacturing and selling prescription medicines. Its recent growth is being driven by strong demand for GLP-1 drugs and other key products, while its pipeline includes olomorasib, which received FDA Breakthrough Therapy designation for advanced pancreatic cancer. The supplied evidence does not provide a segment breakdown or customer mix, so contributions by business line cannot be quantified. Lilly generated $65.2 billion of revenue and $20.6 billion of net income in fiscal 2025, up from $45.0 billion and $10.6 billion, respectively, in 2024.
Eli Lilly fell 8.60%, from $1,220.66 to $1,115.68, declining in every reported session and reaching its lowest close on August 4 as volume rose to 4.10 million shares. The most identifiable company-specific development was the FDA’s Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, announced Monday, but it did not prevent a 2.4% decline that day. Investors were also positioning ahead of the August 5 earnings release, which was outside the reported trading window. Available evidence does not identify a negative company announcement during the week; the sustained retreat therefore appears driven mainly by pre-earnings positioning and broader reassessment of the stock’s valuation and growth expectations.
